WeVote
Log In

Bill

YA

Bill

HR 8734

To express the Sense of Congress with respect to safety of medication abortion and Federal preemption of State restrictions on dispensing medication abortion, and for other purposes.

119th Congress Introduced by Yassamin Ansari and 17 co-sponsors

The bill aims to state Congress’s view on the safety of medication abortion and push federal preemption to override state restrictions on dispensing it.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 8734

Bill at a glance

  • Bill: HR 8734
  • Session: 119 (United States Congress)
  • Title: To express the Sense of Congress with respect to safety of medication abortion and Federal preemption of State restrictions on dispensing medication abortion, and for other purposes.
  • Status: Introduced in the House and referred to the House Committee on Energy and Commerce (as of 2026-05-11).
  • Sponsors: Multiple co-sponsors including Yassamin Ansari, Pat Ryan, Dina Titus, Eleanor Holmes Norton, Judy Chu, Lizzie Fletcher, Gabe Vasquez, and Deborah Ross.

Purpose and intent

  • The primary aim is to articulate the Sense of Congress regarding:
    • The safety of medication-based abortion (as opposed to surgical abortion).
    • Federal preemption of state restrictions on dispensing medication abortion.
  • In broad terms, the bill seeks to support federal standards or preemption to ensure access to medication abortion by limiting or overriding state-level restrictions that could impede dispensing.

Key provisions and changes (as described by the bill’s title)

  • Expression of Congressional Sense: The bill would formally state the sense of Congress on the safety considerations associated with medication abortion. This typically signals the legislative posture or intent of Congress on the issue, though it does not itself create new law or policy.
  • Federal preemption of state restrictions: The bill seeks to establish or acknowledge federal preemption over state-imposed restrictions on dispensing medication abortion. This could mean:
    • Limiting the effect of certain state laws that regulate, restrict, or ban the dispensation of medication abortion pills.
    • Potentially establishing a federal standard or authority to override conflicting state measures regarding how and where medication abortion can be dispensed.
  • Other purposes: The phrase “and for other purposes” suggests additional provisions may be included to support access, safety, or regulatory framework surrounding medication abortion, potentially including regulatory, funding, or enforcement elements, though specific text is not provided in the summary.

Who/what would be affected

  • Healthcare providers and facilities that dispense medication abortion (e.g., clinics, pharmacies, telemedicine providers) could be impacted by changes related to federal preemption and dispensing requirements.
  • States and their regulatory frameworks for abortion medications may face limitations on implementing restrictive dispensing rules or licensing requirements that conflict with federal standards.
  • Patients seeking medication abortion could experience changes in access depending on how federal preemption is implemented and how safety standards are codified.
  • Federal agencies involved in health regulation and enforcement could gain authority to interpret or implement the preemption and safety provisions.

Procedural and timeline aspects

  • Introduction: The bill was introduced in the House and referred to the Committee on Energy and Commerce on May 11, 2026.
  • Next steps: The committee would typically review, potentially hold hearings, and vote on whether to report the bill to the full House for consideration. If reported, it would advance through further legislative steps (floor debates, votes) and reconciliation processes as applicable.
  • Note: As a sense-of-Congress declaration with potential preemption language, the bill’s passage would depend on formal legislative action to enact any binding rules or statutes; the exact text would determine the legal effect and the scope of preemption.

Additional context

  • The bill’s emphasis on safety and federal preemption aligns with ongoing policy debates about medication abortion access and the balance between federal authority and state regulation.
  • The list of co-sponsors indicates bipartisan interest among some legislators, though the final fate and text would determine practical impact.

If you’d like, I can tailor this summary to include hypothetical sample language and potential implementation scenarios, or compare it to related existing laws and court rulings on medication abortion and federal preemption.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.